MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171, the proprietary molecule which forms the basis of ECT-001 Cell Therapy.

Visit link:
ExCellThera announces UM171 mechanism of action

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh